Status of chloroquine and hydroxychloroquine in COVID-19 infection

Savita Ramesh Shahani1*, Lokesh R. Shahani2

1Department of Pharmacology, MGM Medical College, Navi Mumbai, Maharashtra, India
2Department of Psychiatry and Behavioural Science, McGovern Medical School, Houston, Texas, USA

Received: 07 June 2020
Revised: 04 July 2020
Accepted: 08 July 2020

*Correspondence:
Dr. Savita Ramesh Shahani,
Email: drshahani@rediffmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

COVID-19 causing virus is a single stranded RNA virus which has spread across the globe causing human respiratory tract infection. The novel virus which started from Wuhan was named as Wuhan coronavirus or 2019 novel coronavirus (2019-nCov) by the Chinese researchers. The international committee on taxonomy of viruses named the virus as SARS-CoV-2 and the disease as COVID-19. There is preliminary in vitro evidence of the ability of CQ and HCQ to inhibit SARS-CoV-2 activity. Various small group clinical studies conducted in china indicated efficacy of chloroquine and hydroxychloroquine in Covid-19 cases but results were inconclusive. Based on these studies national agencies in various countries issued guidelines mentioning that chloroquine and Hydroxychloroquine are only to be used in clinical trials or emergency use programs. However, USFDA does not recommend use of both these drugs for treatment of COVID-19 cases. Chloroquine and hydroxychloroquine are known to produce dose dependent toxicity including fatal arrhythmias therefore its possible benefit has to be assessed against its risk. Large number of international and national studies are ongoing to assess exact status of chloroquine and hydroxychloroquine for treatment and prophylaxis of COVID-19 infection. Based on these results ICMR recommend to use hydroxychloroquine for prophylaxis of COVID-19 in India and hydroxychloroquine has been is included in schedule H hence they can be sold by pharmaceutical chemists only strictly with a valid prescription and require record to be maintained but chloroquine is still under schedule H which require to be sold with prescription.

Keywords: Chloroquine hydroxychloroquine, COVID-19, SARS-CoV-2

INTRODUCTION

COVID-19 causing virus is a single stranded RNA virus which has spread across the globe causing human respiratory tract infection. This virus has crown-like spikes on their outer surface; thus, it was named as a coronavirus (coronam is the Latin term for crown). The novel virus which started from Wuhan was named as Wuhan coronavirus or 2019-novel coronavirus (2019-nCov) by the Chinese researchers. The international committee on taxonomy of viruses named the virus as SARS-CoV-2 and the disease as COVID-19.1 In January 2020, during the 2019-20 corona virus pandemic, Chinese medical researchers stated that exploratory research into chloroquine (CQ) seemed to have fairly good inhibitory effects on the SARS-CoV-2 virus.2

CQ was discovered in 1934, by Hans Andersag and co-workers’ German scientists at the Bayer laboratories in a process to discover a substitute for quinine as antimalarial agent, and it was named as Resochin.3 In initial evaluation, the drug was discarded, as it was considered too toxic for human use. This was later considered a major mistake (the “resochin error”, using the drug’s German trade name). In 1943 large number of compounds were evaluated for its antimalarial activity in
United State government sponsored clinical trials for antimalarial drug development, and CQ which is a 4-AQ derivative has shown a significant therapeutic value against malarial infection.

CQ has a good oral absorption with bioavailability of around 80%. It has a very large apparent volume of distribution due to extensive sequestration into various tissues particularly liver, spleen, lungs, melanin containing tissue, therefore is widely distributed in body tissues. Its metabolism is partially hepatic, giving rise to its two main metabolites, desethylchloroquine and bis-dese-ethyl chloroquine. Its excretion is ≥50% as unchanged drug in urine, and acidification of urine increases its elimination. It has a terminal half-life of 30-60 days due to slow elimination from storage sites.

CQ is used for treatment of malaria in adults in dose of 600 mg CQ base as loading dose followed by 300 mg at 8, 24 and 48 hours which is equivalent to a total of 1500 mg base (equivalent to 2500 mg of chloroquine phosphate) in 48 hours. It is used as prophylactic regimen in malaria in dose of 300 mg CQ base weekly.

**ADVERSE REACTIONS OF CQ**

Taken in therapeutic dose it is a safe drug however it has a narrow margin of safety. Dose of CQ used for oral therapy may cause some of these following ADRs GIT upset like-nausea, vomiting, diarrhea, abdominal cramps, unpleasant metallic taste.

Dermatological disorder itching, skin color changes, hair loss, and skin rashes. CQ-induced itching is very common among black Africans 70%, may be due to genetic characteristics. In 2014, Stevens-Johnson syndrome was added as an adverse drug reaction into the prescribing information leaflet of chloroquine in India.5 Ocular toxicity like blurring of vision, diplopia, CNS toxicity like headache confusion convulsions. Hematological disorder pancytopenia, aplastic anemia, reversible agranulocytosis, low blood platelets, neutropenia. Cardiovascular toxicity widening of QRS complex and T wave abnormalities.

Prolong therapy used for prophylaxis of malaria may produce toxic myopathy, cardiopathy, peripheral neuropathy and retinopathy. There is not enough evidence to determine whether CQ is safe to be given to people aged 65 and older.

Because of toxicities observed with CQ, another 4AQ derivative hydroxychloroquine (HCQ) was synthesized in 1946 in an attempt to discover less toxic substitute for malaria. HCQ is a hydroxylated derivative of CQ has similar antimalarial activity and was demonstrated to be much less (~40%) toxic than CQ in animals. Study conducted by Finbloom et al shows that HCQ has much lesser incidence of retinopathy compared to CQ. Thus, HCQ can be used safely with minimal risk of toxicity.

**MECHANISM OF ACTION OF CQ AS ANTIMALARIAL AGENT**

CQ is a lysosomotropic agent, therefore it accumulates preferentially in the lysosomes of cells in the body. The pH, for CQ is 8.5, which means that at 8.5 pH it remains as 50% deprotonated and 50% as protonated form, while at physiological pH (7.4) it is about 90% protonated (as per the Henderson-Hasselbalch equation) further at lysosomal pH of 4.6 CQ is protonated up to 99%. As the protonated form is not membrane permeable and quantitative ‘trapping’ of the CQ in lysosomes results. The lysosomotropic character of CQ account for much of its antimalarial activity, the drug concentrates in the acidic food vacuole of the parasite inhibits haem- polymerase of the parasite, leading to the accumulation of soluble haem which is toxic for the parasite. Same lysosomal toxicity is probably responsible for its action against other infections.

**ANTI-VIRAL ACTION OF CQ/HCQ**

Apart from malaria, some of the studies have reported antiviral effects of CQ.6 CQ had been also been proposed as a treatment for COVID-19, as in vitro tests shows inhibition of the severe acute respiratory syndrome (SARS-CoV) virus by CQ. Keyaerts et al reported that CQ acts as an effective inhibitor of the replication of the SARS-CoV in vitro.10 There is preliminary in vitro evidence of the ability of CQ and HCQ to inhibit SARS-CoV-2 activity. Liu et al observed a similar 50% cytotoxic concentration for CQ and HCQ, however, the 50% maximal effective concentration was lower for CQ than HCQ, irrespective of viral load in host cells suggesting CQ may be more efficacious in similar plasma concentration invitro.11

By contrast, Yao et al observed that HCQ was more potent against SARS-CoV-2 than CQ in vitro (EC50 of 0.72 μM and 5.47 μM) respectively.12 Wang et al reported in vitro antiviral activity of CQ, with an EC50 of 1.13 μM and CC50 >100 μM with high selectivity for SARS-CoV-2 rather than host cells.13 This concentration of CQ is much less than the plasma concentration achieved in human in treatment of malaria with usual dose of 25 mg/kg over 3 days, however dose of 3.6 mg/kg/week which is used for prophylaxis of malaria may produce plasma concentration of 1-3 μmol/l which is the concentration range equivalent to require for IC50 for SARS-CoV2 inhibition. HCQ has shown greater efficacy in in vitro studies. Future studies might tell us most effective schedule of administration and potential adverse events.

**MECHANISM OF ACTION OF CQ/HCQ IN COVID-19**

The main target cells of CQ for the SARS-CoV-2 are in enterocytes and pneumocytes in which it enters in high concentration after administration. CQ increases...
endosomal and lysosomal pH and inhibits entry of SARS-CoV-2 into cells as well as inhibit viral replication. The author speculated that CQ and HCQ in addition could have impact on disease severity in COVID-19 through modulating the excess cytokine release by mediating an anti-inflammatory response, which might reduce damage due to the exaggerated inflammatory response. CQ also seems to act as a zinc ionophore that allows extracellular zinc to enter the cell and inhibit viral RNA-dependent RNA polymerase.

**EFFECT OF CQ/HCQ AGAINST COVID-19 PATIENTS**

A great deal of effort has been made to find effective drugs against the COVID-19 in China, as this infection started from this country. Most guidelines cite interim results of two studies. A brief study mentioning results from more than 100 patients have demonstrated that CQ is superior to the conventional treatment in inhibiting the exacerbation of pneumonia, improving lung imaging findings, promoting a virus negative conversion, and shortening the disease course.

In a pilot study aiming to evaluate the efficacy and safety of CQ in inpatients with COVID-19, 10 patients (3 with severe disease and 7 with moderate disease) received CQ (300 mg base) orally twice a day for 10 days, and 12 patients (5 with severe disease and 7 with moderate disease) received lopinavir and ritonavir 400 mg and 100 mg orally twice a day for 10 days. CQ was slightly superior to lopinavir and ritonavir in terms of virus clearance, since the CQ group tested negative for SARS-CoV-2 at slightly better rate than the control group on 7, 10, and 14 days post-treatment. However, CQ was superior to lopinavir and ritonavir in improving the radiological appearance of the lungs and decreasing the duration of hospitalization. All ADRs observed with CQ were tolerable and CQ was not discontinued in any of the patients during the treatment period. Due to its promising preliminary information, CQ has been included in guidelines for the diagnosis and treatment of COVID-19 (sixth edition) published by the National Health Commission of the People’s Republic of China.

CQ has also been approved by, South Korean and Italian health authorities for the experimental treatment of COVID-19. These agencies notified people with heart disease and diabetes as contraindications. On March 28th 2020 the USFDA authorized the use of HCQ and CQ under an emergency use authorization which was revoked back on 15th June 2020. On 1 April 2020, the European medicines agency issued guidelines that CQ and HCQ are only to be used in clinical trials or emergency use programs. The Indian Council of Medical Research (ICMR), has recommended chemoprophylaxis with HCQ for asymptomatic healthcare workers treating patients with suspected or confirmed COVID-19, and for asymptomatic household contacts of confirmed cases. This was revised on 23rd May 2020 to expand its indication.

**SOME OF THE CLINICAL TRIALS REGARDING USE OF CQ/HCQ IN COVID-19**

Exact status of CQ/HCQ as pharmacotherapy of COVID-19 still required to be assessed. Result of some of the published work is discussed here. A parallel, double-blinded, randomized, phase 2b clinical trial to assess the safety and efficacy of 2 different doses of CQ as adjunctive therapy of hospitalized patients with severe acute respiratory syndrome (SARS) due to COVID-19 was planned in Brazil. Participants were randomized to either high or low dose of CQ. Patients in high dose CQ group received 600 mg CQ base twice daily dose over 10 days (a total of 12 gm total dose over 10 days), while patients in low dose CQ received 450 mg of CQ base twice daily on day 1 and once daily for next 4 days (a total of 2.7 gm in five days). The study was halted temporarily after enrolling 81 patients, as by 6th day 11 participants died. On decoding it was observed that the group of patients taking a high dose of the CQ, some of them developed dangerous heart rhythm problems. It was seen more often in older patients with concomitant use of azithromycin (AZ) which also prolong QTc interval. As a consequence study was halted in high dose CQ group and shifted them to low dose CQ.

On April 24 the USFDA cautioned against using the drug outside a hospital setting or clinical trial after reviewing adverse events including ventricular tachycardia, ventricular fibrillation, and death. During this time of crisis it is important to prioritize clinical trials evaluating important questions regarding CQ, such as its dosing in prophylaxis, and treatment in COVID-19. It is also important to convey clear messages that reflect the proper interpretations of available data which must be disseminated.

In COVID-19 clinical trial, one small non-randomized study from France demonstrated beneficial effect of HCQ. This study with 36 participants had a variable patient profile like, 6 asymptomatic, 22 with upper respiratory tract infection symptoms and eight with lower respiratory tract infection symptoms. While another six patients who were not the part of study were considered as control, who received standard care. Out of 36 participants 26 patients received HCQ along with standard care while remaining 10 participants received standard care. Twenty cases receiving HCQ showed a significant reduction of the viral load on Day-6-post CQ treatment, compared to controls, and much lower average carrying duration compared to untreated patients in the literature. AZ added to HCQ in 6 patients was significantly more efficient for virus elimination. Six participants receiving HCQ were lost to follow up and author concluded that HCQ treatment is associated with significant (p<0.001) viral load reduction/disappearance in Covid-19 patients and its effect is potentiated by AZ.
This study has some limitations including a small sample size which is not sufficient to achieve sufficient power in statistics, limited long-term outcome follow-up, and dropout of six patients from the study which were not considered during statistical analysis. In addition, this study lacked matching control group, however in the current context, author felt that these results should be shared with the scientific community.

Yet, another very small, randomized study from China in patients with mild to moderate COVID-19 found no difference in recovery rates in patients treated with HCQ (400 mg per day for 5 days plus conventional treatments), compared to control group receiving conventional medical care only. 27 author concludes that larger sample size study may be needed to investigate the effects of HCQ in the treatment of COVID-19.

Similar findings were observed by Boulware et al who conducted a randomized, double-blind, placebo-controlled trial in United States and Canada testing HCQ as post-exposure prophylaxis in asymptomatic participants who had known exposure to a person with laboratory-confirmed Covid-19, like a household contact, health care worker, person with other occupational exposures. All participants received either HCQ in dose of 800 mg once, then after 6 to 8 hours 600 mg as a loading dose, followed by 600 mg daily for 4 more days for a total course of 5 days (total 3800 mg) or matching placebo. This trial did not demonstrate any significant benefit of HCQ as post-exposure prophylaxis for COVID-19 up to 14 days of follow up. This study had not explored its role in pre-exposure prophylaxis.29 There was no serious intervention-related adverse reactions including cardiac arrhythmias. Limitation of this study was that approximately 60% of the participants were not using any personal protective equipment during their COVID-19 exposure. Time of exposure to COVID-19 patient and intake of interventional agent was not uniform. All participants under study did not have confirmed lab test for virus, majority of them were assessed based on COVID-19 related symptoms thus asymptomatic infected people were not added in interventional group. Outcome of study was assessed based on information given by participants through internet.

In addition to efficacy, 4AQs can cause ventricular arrhythmias, QT prolongation, and other cardiac toxicity, which may pose risk particularly to critically ill persons. Therefore, well-performed randomized trials that can clarify exact status of CQ and HCQ in COVID-19. Wide use of HCQ may expose some patients to rare but potentially fatal harms, including serious cutaneous adverse reactions, fulminant hepatic failure, and ventricular arrhythmias (especially when prescribed with AZ).29-31 Moreover, the safety of these immunomodulation by HCQ in people at risk of a severe viral illness has never been evaluated.

As of now, supportive care is the therapy for majority of COVID-19 cases. It is very important that healthcare professionals use CQ and HCQ only for their authorized uses or as part of clinical trials or national emergency use programs for the treatment of COVID-19. Both CQ and HCQ can have serious side effects, especially at high doses or when combined with other medicines. Large clinical trials are under way to generate the data needed to establish the efficacy and safety of CQ and HCQ in the treatment of COVID-19.

Some of the ongoing clinical trials related to CQ in covid-19 are mentioned below. A large, randomized multicentric phase III clinical trial, discovery (clinical trials.gov identifier: NCT04315948), sponsored by Institute National de la Sante Et de la Recherche Medicaile, France involves all COVID-19 confirmed patients with moderate disease. All participants will be given usual standard of care. While intervention group will receive apart from standard care any one of following treatment remdesivir, lopinavir and ritonavir, lopinavir and ritonavir plus interferon β-1a 4-hydroxychloroquine. The primary endpoint of the study was clinical status of patients after 2 weeks to assess efficacy and safety of various regimens.32

This clinical trial (clinical trials.gov identifier: NCT04328493) is sponsored by Oxford University Clinical Research Unit, Vietnam. This is a phase II open label, randomized, controlled trial that will be conducted in in-patients with aim to evaluate potential therapeutics of CQ in the treatment of hospitalized COVID-19. The study will start as observational pilot study and once initial results are approved by data safety board regular study will be conducted in 250 participants. Patients will be randomized to the intervention arm who will receive CQ (loading dose of 1200 mg CQ base over the first 24 hours followed by 300 mg once daily for 9 days) along with standard of care therapy, while control arm will receive only standard care therapy. All participants will be assessed up to 56 days post randomization for time to viral clearance and safety of drug.33

Clinical trials.gov identifier: NCT04370262 sponsored by Northwell Health USA is a multi-site, randomized, double-blind, multi-arm historical control, comparative trial to assess safety and efficacy of HCQ alone, and the combination of HCQ and famotidine for the treatment of moderate to severe COVID-19. Since HCQ became the standard care treatment for COVID-19 shortly after this time period, researcher felt it would be unethical to randomize patients in this trial to a control arm without any active investigational medications. This study will review data previously collected on patients not treated with HCQ to compare to the active treatment arms. About 1200 COVID-19 participants will receive a loading dose of HCQ 400 mg twice daily on day 1, followed by 200 mg twice daily for 4 days, or a loading dose of 800 mg 4 times daily on day 1, followed by 400 mg 4 times daily for 4 days, as per clinical protocol for COVID-19. In
addition, participants will receive intravenous famotidine, 120 mg, (the total daily dose proposed is 360 mg/day)/placebo as per randomization for a maximum of 14 days. The aim of study is to compare mortality status, viral clearance and severity of disease between 2 interventional groups up to follow up period of 30 days. The interventional group will be compared with historical control.\textsuperscript{34} This study was designed based on the retrospective cohort study conducted by Freedberg et al who observed that use of famotidine is associated with reduced risk of intubation or death in hospitalized COVID-19 patients.\textsuperscript{35}

Clinical trials.gov identifier: NCT04333628 sponsored by HaEmek Medical Center, Israel to assess effect of CQ for mild symptomatic and asymptomatic COVID-19. The purpose of this study is to test whether a low dose of CQ will reduce the duration of the viral shedding and prevent the disease from worsening. This is a phase 2 and phase 3 trial in 210 participants. The trial will be conducted in two stages. In first phase patients with mild-grade symptomtology disease will receive either low dose of CQ (125 mg daily) or regular dose of CQ (500 mg twice daily) for 7 days, while the control group will receive only standard care. Depending on the results of the first phase, Investigators will consider the second stage, in asymptomatic carriers to study whether CQ therapy in asymptomatic patients decrease duration of viral shedding and prevent the onset of symptomatic disease.\textsuperscript{36}

Clinical trials.gov identifier: NCT04303507 sponsored by University of Oxford entitled will be conducted in 40,000 participants from various countries. The study is a double-blind, randomized, placebo-controlled trial involving around 40,000 healthcare workers in a healthcare facility delivering direct care to patients with proven or suspected COVID-19. The participant will be randomized in Asia to receive either CQ base in loading dose of 10 mg base/kg (4x155 mg) followed by 155 mg daily or placebo, or in European and African sites, HCQ 200 mg daily or placebo for 90 days. If the participant is diagnosed with COVID-19, they will continue to take the study medication unless advised to stop by their healthcare professional. The study is aimed to assess difference in number of symptomatic COVID-19 cases between the CQ/HCQ and placebo groups.\textsuperscript{37} There are 3 registries on CTRI site for clinical trials on ‘CQ and COVID-19 to be conducted in India.

CTR number CTRI/2020/05/025067. It is a multicentric randomized, parallel group, controlled trial of HCQ prophylaxis for healthcare workers exposed to COVID-19, which is sponsored by George Institute for Global Health India. Study is aimed to compare whether 800 mg of HCQ on the day of enrollment followed by 400 mg weekly for a total of 12 weeks along with standard care personal protection, has any protective effect in terms of proportion of laboratory confirmed symptomatic COVID-19 cases compared to standard care personal protection.\textsuperscript{38} CTRI number CTRI/2020/04/024904. It is a randomized parallel group, controlled clinical trial to compare efficacy of HCQ alone and in combination with AZ in treatment of COVID-19 which is sponsored by Director General Armed Forces Medical Services New Delhi. Aim of study is to compare if there is any difference in outcome of patients treated with high dose HCQ (600 mg BD D1, HCQ 300 mg BD D2-D50 vs low dose HCQ 400 mg BD on D1 and 400 mg OD on D2-SI) vs low dose HCQ and AZ in two different doses taken together (HCQ 400 mg BD AZT 500 mg OD vs D1 HCQ 400 mg OD AZT 250 mg OD D2-D5).\textsuperscript{39}

CTR number CTRI/2020/04/024479. It is an open labeled randomized parallel group, controlled trial to study the effect of CQ in addition to standard therapy in Covid-19 patients which is sponsored by Command Hospital Bangalore. Study is aimed to compare effect of chloroquine phosphate (500 mg twice daily for 10 days compared to standard treatment to observe if there is any difference in number of days of hospitalization /discharge between the 2 groups.\textsuperscript{40}

CTR number CTRI/2020/03/024402. This is a randomized, parallel group in open labeled, clinical trial to assess efficacy of HCQ treatment in conventional dose as per ICMR regimen (400 mg twice daily for one day followed by 400 mg weekly for 7 weeks) vs low dose (300 mg daily x7 days followed by 300 mg weekly x7 weeks) for prevention of new infection and adverse outcomes following COVID-19. The study is sponsored by Aster Malabar Institute of Medical Sciences. Kozhikode Kerala.\textsuperscript{41}

**“SOLIDARITY” CLINICAL TRIAL FOR COVID-19 TREATMENTS**\textsuperscript{42}

“Solidarity” is an international clinical trial to help find an effective treatment for COVID-19, launched by the WHO and partners. This study was planned to compare four treatment options against standard of care, to assess their relative effectiveness against COVID-19 to assess whether any of the drugs reduce disease progression or improve survival. COVID-19 patient is randomized to receive either only standard care or one of the following four regimens with standard care remdesivir, HCQ, lopinavir and ritonavir, lopinavir and ritonavir plus interferon beta-1a. The outcome of various regimens will be compared in terms of duration of hospital stay, supportive care needed, outcome of treatment.

The ICMR, has recommended chemoprophylaxis with HCQ (400 mg twice on day 1, then 400 mg once a week for 7 weeks) for asymptomatic healthcare workers treating patients with suspected or confirmed COVID-19, and for asymptomatic household contacts of confirmed cases (400 mg twice on day 1, then 400 mg once a week for 3 weeks).\textsuperscript{23}
Chinese guidelines advise consideration of CQ in all hospitalized patients, although has advised caution regarding dosing and special patient groups.\textsuperscript{43} The WHO, the US centers for disease control and prevention, and public health England are yet to recommend CQ or HCQ for treatment.\textsuperscript{44} To reduce the risk of adverse effects of CQ, the Republic of China seventh in edition of the guidance, issued on 3 March 2020, recommended to reduced dosage and shortened duration of treatment. Recommended dose of CQ for adult patients with a body weight >50 kg is 500 mg twice a day for 7 days and for adult with body weight <50 kg is 500 mg twice a day for the first 2 days and 500 mg once a day for the following 3-7 days.\textsuperscript{45}

A multi-national registry analysis was done to assess efficacy of use of HCQ or CQ with or without a macrolide for treatment of COVID-19. The registry comprised data from 671 hospitals in six continents. Study included patients hospitalized with a SARS-CoV-2 infection. Patients who received one of the treatments of interest within 48 hours of diagnosis were included in one of four treatment groups (CQ alone, CQ with a macrolide, HCQ alone, or HCQ with a macrolide), and patients who received none of these treatments formed the control group to assess in-hospital mortality and the occurrence of de-novo ventricular arrhythmias. 96032 patients hospitalized with COVID-19 during the study period were included in the study, out of them 14888 patients were in the treatment groups (1868 received CQ, 3783 received CQ with a macrolide, 3016 received HCQ, and 6221 received HCQ with a macrolide) and 81144 patients were in the control group. After controlling for multiple confounding factors when various groups were compared to control, it was observed that each group of interventional drugs were independently associated with an increased risk of in-hospital mortality and de-novo ventricular arrhythmia during hospitalization. Therefore, author interpreted that results do not support benefit of HCQ or CQ, when used alone or with a macrolide, in hospitalized COVID-19 patients.\textsuperscript{46}

Based on the findings of the above online publication WHO suspended temporarily HCQ arm in the solidarity trial, till safety data is reviewed by the data safety monitoring board. WHO chief scientist clarified that the WHO-backed solidarity trial is planned to consider only at the effects of HCQ and not CQ. Based on the information available if HCQ is to be used, a clear informed choice needs to be offered to every contact, explaining the scarcity of evidence for its efficacy and its potential risks. Additionally, all outcome events should be recorded for the risk–benefit assessment.\textsuperscript{47} On 3\textsuperscript{rd} June 2020, WHO’s director-general, mentioned that the board reviewed the available mortality data and found “no reasons to modify the trial.” and allowed the investigators to resume their clinical trial.\textsuperscript{48}

ICMR updated its advisory on 23\textsuperscript{rd} May 2020, to extend the usage of HCQ as a preventive treatment against the SARS-CoV-2 infection. Based on the findings of the studies, the government has decided to administer HCQ as a prophylaxis to asymptomatic healthcare workers working in non-COVID hospitals, non-COVID blocks of hospitals earmarked for COVID-19 treatment, asymptomatic frontline workers, such as surveillance workers deployed in containment zones, paramilitary and police personnel involved in COVID-related activities. While the dosage will remain the same as before for eight weeks, the ICMR advisory suggests that it can be used beyond that period as well, but with close monitoring of clinical and ECG parameters, to ensure that the therapy is given under supervision.\textsuperscript{49}

This advisory is issued based on a retrospective case-control analysis at ICMR showing that there is a significant dose-response relationship between the number of prophylactic doses taken and frequency of occurrence of SARS-CoV-2 infection in symptomatic healthcare workers. However, in final results of the studies (HCQ prophylaxis among 1323 healthcare workers), ICMR observed mild adverse effects such as nausea, abdominal pain, vomiting, hypoglycaemia and cardio-vascular effects. The advisory states that the drug should be discontinued if it causes the rare cardiac side effects such as cardiomyopathy, heart-rate disorders and visual disturbance including blurring of vision, which is usually self-limiting and improves on discontinuation of the drug. ICMR has clarified that “for the above cited reasons the drug has to be given under strict medical supervision with an informed consent”. The drug is not recommended for prophylaxis in children under 15 years of age and in pregnancy and lactation, the advisory said. ICMR has not issued any guidelines for use of CQ in COVID-19 cases. Another investigation from 3 central government hospitals in New Delhi indicates that amongst healthcare workers involved in COVID-19 care, those on HCQ prophylaxis were less likely to develop SARS-CoV-2 infection, compared to those who were not on it. In an observational prospective study of 334 healthcare workers at AIIMS New Delhi, it was observed that 248 participants who took HCQ prophylaxis had lower incidence of SARS-CoV-2 infection than those not taking it.

As seen with different studies investigators have used different doses. Again, doses used for prophylaxis of CQ/HCQ is much lesser than if used for therapeutics. As both HCQ and CQ causes dose and duration dependent toxicity, therefore given for prophylaxis for appropriate duration may be less likely to cause toxicity. Therefore, ICMR has issued a strict advisory mentioning that they must not be used without a prescription and without supervision by a physician and prescriptions should not be given outside their authorized uses. Therefore, the gazette of INDIA on 26th March, 2020 notified that HCQ is included in schedule H1 hence they can be sold by pharmaceutical chemists strictly with a valid prescription and separate register recording identity of the patient, contact details of the prescribing doctor and the name and
dispensed quantity of the drug should be maintained. This record required to be retained for at least three years so a clear overview regarding consumption of HCQ can be obtained. This notification also does not put any restriction on use of CQ which is still under schedule H which requires to be sold with prescription but need not maintain its record.50

CONCLUSION

It is also important to convey clear messages that reflect the proper interpretations of available data regarding management of COVID-19, which must be disseminated. Physicians should be educated about the correct assessment of available data regarding HCQ and CQ in treating COVID-19, so that they can avoid misuse of HCQ and CQ especially for the prophylaxis of SARS-CoV-2 infection. Well planned, clinical trials which are ongoing may take through data regarding potential therapies, including the risk for serious adverse events, as current data to support the use of HCQ and CQ for COVID-19 are limited and inconclusive. Again, most of the recent studies and regulatory guidelines are regarding use of HCQ. Therefore, physicians should be educated about advantage of one drug over other to decide selection of CQ if at all this is prescribed by them.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: Not required

REFERENCES


